ADMA BIOLOGICS, INC. Basic Shares Outstanding (Weighted Average)
ADMA BIOLOGICS, INC. (ADMA) reported Basic Shares Outstanding (Weighted Average) of 228.23 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-05
- ADMA BIOLOGICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 228.23M shares, a 5.49% decline year-over-year.
- ADMA BIOLOGICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 236.07M shares, a 0.72% decline year-over-year.
- ADMA BIOLOGICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 237.97M shares, a 0.64% increase year-over-year.
- ADMA BIOLOGICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 238.60M shares, a 1.72% increase year-over-year.
- ADMA BIOLOGICS, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 238.30M shares, a 2.24% increase from fiscal 2024.
- ADMA BIOLOGICS, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 233.08M shares, a 4.07% increase from fiscal 2023.
- ADMA BIOLOGICS, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 223.98M shares, a 13.19% increase from fiscal 2022.
- ADMA BIOLOGICS, INC. weighted average number of shares outstanding, basic for fiscal 2022 was 197.87M shares, a 41.77% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 228.23M shares 10-Q · filed 2026-08-05 | 232.14M shares 10-Q · filed 2026-08-05 | 234.09M shares derived: average of 3 quarters · filed 2026-08-05 | 235.22M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 236.07M shares 10-Q · filed 2026-05-06 | 237.02M shares derived: average of 2 quarters · filed 2026-05-06 | 237.55M shares derived: average of 3 quarters · filed 2026-05-06 | 238.53M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | 237.97M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 238.29M shares derived: average of 2 quarters · filed 2026-02-25 | 239.36M shares derived: average of 3 quarters · filed 2026-08-05 | 238.30M shares 10-K · filed 2026-02-25 |
| 2025-09-30 | 238.60M shares 10-Q · filed 2025-11-05 | 240.05M shares derived: average of 2 quarters · filed 2026-08-05 | 238.41M shares 10-Q · filed 2025-11-05 | 238.58M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | 241.49M shares 10-Q · filed 2026-08-05 | 238.31M shares 10-Q · filed 2026-08-05 | 238.57M shares derived: average of 3 quarters · filed 2026-08-05 | 237.57M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | 237.78M shares 10-Q · filed 2026-05-06 | 237.12M shares derived: average of 2 quarters · filed 2026-05-06 | 236.27M shares derived: average of 3 quarters · filed 2026-05-06 | 235.31M shares derived: average of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | 236.46M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 235.51M shares derived: average of 2 quarters · filed 2026-02-25 | 234.48M shares derived: average of 3 quarters · filed 2026-02-25 | 233.08M shares 10-K · filed 2026-02-25 |
| 2024-09-30 | 234.57M shares 10-Q · filed 2025-11-05 | 233.49M shares derived: average of 2 quarters · filed 2025-11-05 | 231.96M shares 10-Q · filed 2025-11-05 | 230.46M shares derived: average of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | 232.42M shares 10-Q · filed 2025-08-06 | 230.65M shares 10-Q · filed 2025-08-06 | 229.09M shares derived: average of 3 quarters · filed 2026-02-25 | 228.14M shares derived: average of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | 228.87M shares 10-Q · filed 2025-05-07 | 227.43M shares derived: average of 2 quarters · filed 2026-02-25 | 226.71M shares derived: average of 3 quarters · filed 2026-02-25 | 225.71M shares derived: average of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | 225.99M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 225.63M shares derived: average of 2 quarters · filed 2026-02-25 | 224.65M shares derived: average of 3 quarters · filed 2026-02-25 | 223.98M shares 10-K · filed 2026-02-25 |
| 2023-09-30 | 225.28M shares 10-Q · filed 2024-11-07 | 223.98M shares derived: average of 2 quarters · filed 2024-11-07 | 223.31M shares 10-Q · filed 2024-11-07 | 218.19M shares derived: average of 4 quarters · filed 2025-03-18 |
| 2023-06-30 | 222.68M shares 10-Q · filed 2024-08-08 | 222.30M shares 10-Q · filed 2024-08-08 | 215.83M shares derived: average of 3 quarters · filed 2025-03-18 | 210.97M shares derived: average of 4 quarters · filed 2025-03-18 |
| 2023-03-31 | 221.92M shares 10-Q · filed 2024-05-09 | 212.40M shares derived: average of 2 quarters · filed 2025-03-18 | 207.06M shares derived: average of 3 quarters · filed 2025-03-18 | 204.39M shares derived: average of 4 quarters · filed 2025-03-18 |
| 2022-12-31 | 202.88M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 199.63M shares derived: average of 2 quarters · filed 2025-03-18 | 198.54M shares derived: average of 3 quarters · filed 2025-03-18 | 197.87M shares 10-K · filed 2025-03-18 |
| 2022-09-30 | 196.38M shares 10-Q · filed 2023-11-08 | 196.37M shares derived: average of 2 quarters · filed 2023-11-08 | 196.20M shares 10-Q · filed 2023-11-08 | 192.47M shares derived: average of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | 196.35M shares 10-Q · filed 2023-08-09 | 196.11M shares 10-Q · filed 2023-08-09 | 191.16M shares derived: average of 3 quarters · filed 2024-02-28 | 176.82M shares derived: average of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | 195.87M shares 10-Q · filed 2023-05-10 | 188.57M shares derived: average of 2 quarters · filed 2024-02-28 | 170.30M shares derived: average of 3 quarters · filed 2024-02-28 | 159.58M shares derived: average of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | 181.27M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 157.52M shares derived: average of 2 quarters · filed 2024-02-28 | 147.48M shares derived: average of 3 quarters · filed 2024-02-28 | 139.58M shares 10-K · filed 2024-02-28 |
| 2021-09-30 | 133.77M shares 10-Q · filed 2022-11-09 | 130.59M shares derived: average of 2 quarters · filed 2022-11-09 | 125.68M shares 10-Q · filed 2022-11-09 | 118.39M shares derived: average of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | 127.42M shares 10-Q · filed 2022-08-10 | 121.57M shares 10-Q · filed 2022-08-10 | 113.26M shares derived: average of 3 quarters · filed 2022-08-10 | 106.87M shares derived: average of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | 115.66M shares 10-Q · filed 2022-05-11 | 106.18M shares derived: average of 2 quarters · filed 2022-05-11 | 100.02M shares derived: average of 3 quarters · filed 2022-05-11 | 96.60M shares derived: average of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | 96.70M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | 92.20M shares derived: average of 2 quarters · filed 2022-03-24 | 90.25M shares derived: average of 3 quarters · filed 2022-03-24 | 86.15M shares 10-K · filed 2022-03-24 |
| 2020-09-30 | 87.70M shares 10-Q · filed 2021-11-10 | 87.02M shares derived: average of 2 quarters · filed 2021-11-10 | 82.63M shares 10-Q · filed 2021-11-10 | |
| 2020-06-30 | 86.35M shares 10-Q · filed 2021-08-11 | 80.06M shares 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |